Pharmafile Logo

Navigating challenges of MedTech research with rare-disease patients

February 16, 2024 | Medtech, Patient research, rare diseases 

Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk’s Magazine.

As technology advances there is a growing array of MedTech solutions – wearables, voice-activated devices, telehealth, etc. – to better support patients in- PMLiVE their daily lives. However, MedTech research with rare-disease patients presents several unique challenges that must be considered. Ideally, interviews would be in-person in a central location to observe device use; the rarity of the condition can lead to the need for a hybrid methodological approach. In this article, we will: provide some background on rare disease and how research can be different in this population; describe different methodological approaches, respondent configurations and recruitment considerations; and discuss aspects of moderation and analysis.

Read the article here.

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Quantitative specialist joins Research Partnership, London

Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London

Webcast

Amplifying the patient voice: How to conduct patient research sensitively to uncover emotional insights

Webcast

The power of a good story: Turn your insights into effective storytelling with data visualisation

Article

How will COVID-19 affect uptake of vaccinations against other diseases?

Podcast

Living With Chronic Illness (Series one)

Webcast

China: How pharma can maximize success in this rapidly changing emerging market

Article

Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma

Infographic

Migraine market snapshot

Webcast

Monitoring the impact of COVID-19 on the market access landscape

Live webinar from Singapore

Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19